BioStream

BioStream operates at the intersection of neurological diagnostics, proteomics and digital health. Its proposed differentiation is the use of urine rather than more invasive or procedure-dependent sampling to support the differential diagnosis of normal pressure hydrocephalus and dementia-related conditions. The platform combines a proprietary urine biomarker panel with machine-learning interpretation, aiming to translate molecular signals into clinician-facing diagnostic insights. That limits the ability to assess market share or defensibility relative to other brain-health diagnostics companies. The multi-center validation effort, involving more than 100 hydrocephalus samples and 50 dementia controls, is the clearest indicator of market relevance, although its results and regulatory pathway remain undisclosed. BioStream’s position is best characterized as an early-stage clinical diagnostics developer with a focused use case and an unproven commercial footprint.

BioStream appears to be in an early clinical-development phase. It was founded on Jan 1, 2025, and Meital Segev-Bar became a Co-Founder and CEO on Feb 1, 2025. The company’s stated product direction has progressed beyond a general research concept toward a defined workflow: urine collection, proteomic testing, biomarker-panel analysis and AI-supported interpretation for neurological diagnosis. Its principal inflection point is the multi-center validation program involving more than 100 hydrocephalus samples and 50 dementia control samples. There is also no disclosed funding history, valuation, investor base or employee-growth series. The current record indicates one featured employee position and an estimated workforce of 1–10 people, suggesting a small operating team. Overall, BioStream’s trajectory is defined by technical and clinical validation rather than financing or revenue expansion.